Biocon: Financial Results for the quarter and half year ended September 30,2026

What happened

Biocon (BIOCON) filed a disclosure with the exchanges on 4 November 2026 at 01:18 PM titled "Financial Results for the quarter and half year ended September 30,2026".

Company snapshot

Biocon is a mid-cap company in the Healthcare sector, with a market value of about ₹55,899 crore.

The stock last traded at ₹343, against a 52-week range of ₹318.4–₹447.2 (23.3% below the high).

Before this filing the shares had moved −7.5% over the month and −18.7% over three months. Average daily turnover over the last 20 sessions was about ₹99.65 crore.

Promoters held 44.68% at the end of Q1 FY27. Foreign institutions owned 8.14% and domestic institutions 23.38%.

What history shows

This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.

Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +2.0% over five days; 57% of them rose the next day.

Market-wide, 10,609 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.
• 4 November 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

• BIOCON: Consolidated revenue grew, but lower profit and weaker Services results tempered performance — TradingView, 4 Nov 2026
• Biocon, Syngene in focus post-Q2 results — Zee Business, 30 Oct 2026
• Biocon Limited (BIOCON.NS) Seasonal returns chart — Yahoo Finance UK, 2 Nov 2026
• Natural Biocon (India) Ltd. Estimates – BSE:NATURAL — TradingView, 23 Oct 2026
• stock in news biocon lupin sri lotus pharma stocks action — Zee Business, 4 Nov 2026

Source

• Exchange filing (PDF)